Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection
Hamidreza Karimi‐Sari(Johns Hopkins University), Joseph K. Lim(Yale Cancer Center), Oluwaseun Falade‐Nwulia(Johns Hopkins University), Mohammad Saeid Rezaee‐Zavareh(Middle East Liver Disease Center)
Cited by 1
Related Papers
Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|728
Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection
|Annals of Internal Medicine|2017|694